



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


# PRODUCT INFORMATION



## Lirafugratinib

Item No. 40940

**CAS Registry No.:** 2549174-42-5  
**Formal Name:** N-[4-[4-amino-5-[3-fluoro-4-[(4-methyl-2-pyrimidinyl)oxy]phenyl]-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-2-methyl-2-propenamide  
**Synonym:** RLY-4008  
**MF:** C<sub>28</sub>H<sub>24</sub>N<sub>7</sub>O<sub>2</sub>  
**FW:** 509.5  
**Purity:** ≥98%  
**Supplied as:** A solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

Lirafugratinib is supplied as a solid. A stock solution may be made by dissolving the lirafugratinib in the solvent of choice, which should be purged with an inert gas. Lirafugratinib is sparingly soluble (1-10 mg/ml) in DMSO.

### Description

Lirafugratinib is a covalent inhibitor of FGFR2 (IC<sub>50</sub> = 0.003 μM).<sup>1</sup> It is selective for FGFR2 over FGFR1, -3, and -4 (IC<sub>50</sub>s = 0.77, 0.26, and 15 μM, respectively). Lirafugratinib inhibits the proliferation of SNU-16 gastric cancer cells (IC<sub>50</sub> = 0.002 μM). *In vivo*, lirafugratinib (10 mg/kg) reduces intratumoral FGFR2 phosphorylation and tumor volume in an FGFR2-amplified SNU-16 gastric cancer mouse xenograft model.

### Reference

- Schönherr, H., Ayaz, P., Taylor, A.M., *et al.* Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2. *Proc. Nat. Acad. Sci. USA* **121**(6), e2317756121 (2024).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/17/2024

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM